GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: 1mg Glimepiride/10mg Atorvastatin FDCDrug: 2mg Glimepiride/10mg Atorvastatin FDCDrug: 3mg Glimepiride/10mg Atorvastatin FDCDrug: 4mg Glimepiride/10mg Atorvastatin FDCDrug: 1mg Glimepiride/20mg Atorvastatin FDCDrug: 2mg Glimepiride/20mg Atorvastatin FDCDrug: 3mg Glimepiride/20mg Atorvastatin FDCDrug: 4mg Glimepiride/20mg Atorvastatin FDC
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 427
- Registration Number
- NCT01495013
- Locations
- 🇹🇭
GSK Investigational Site, Rajathevee, Thailand
Study in Pediatric Subjects With Epilepsy
Phase 2
Terminated
- Conditions
- Epilepsy
- Interventions
- Drug: ezogabine/retigabine
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT01494584
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Crohn's Disease
- Interventions
- Drug: GSK1605786 500 mg
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01489943
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
Phase 1
Completed
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: Pneumococcal vaccine GSK2830930ABiological: Synflorix™
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT01485406
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Airflow Limitation in Cardiac Diseases in Europe
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Procedure: Spirometry
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3000
- Registration Number
- NCT01485159
- Locations
- 🇸🇪
GSK Investigational Site, Malmö, Sweden
Gabapentin and Donepezil Combination on Experimental Human Pain Models
Phase 1
Completed
- Conditions
- Pain, Neuropathic
- Interventions
- Other: Placebo (Dop)Other: Placebo (Gaba)
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT01485185
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease
Phase 4
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: placebo monotherapy
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 186
- Registration Number
- NCT01485172
- Locations
- 🇸🇰
GSK Investigational Site, Bratislava, Slovakia
Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT01485445
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: TDF tablets
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT01480622
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT01480609
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath